Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Final clinical results of N-803 BCG Unresponsive NMIBC Trial
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1035)
•••
Comment by enriquesuaveon May 14, 2022 10:59pm
289 Views
Post# 34684503

RE:Final clinical results of N-803 BCG Unresponsive NMIBC Trial

RE:Final clinical results of N-803 BCG Unresponsive NMIBC Trial

Same results as before.  Very good, but it's also a combination therapy  2 drugs will always work synergistically and give added efficacy.  TLD-1433 single agent should give us results very close to those IMO after full trial results, but we will be 1 single treatment vs 15-21 instillations.  All IMHO 


Eoganacht wrote:  were presented at the AUA2022 yesterday, Friday, May 13. We already knew the results - Cohort A  (83 patients with CIS) achieved - 71% CR at any time - 36% CR at 2 years.  Cohort B (77 patients with papillary disease) achieved a disease-free survival rate of 57% at 12 months and 48% at 24 months.

Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities